110 related articles for article (PubMed ID: 25038326)
1. Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients.
Bol KF; Mensink HW; Aarntzen EH; Schreibelt G; Keunen JE; Coulie PG; de Klein A; Punt CJ; Paridaens D; Figdor CG; de Vries IJ
Am J Ophthalmol; 2014 Nov; 158(5):939-47. PubMed ID: 25038326
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses.
Dillman RO; Cornforth AN; Nistor GI; McClay EF; Amatruda TT; Depriest C
J Immunother Cancer; 2018 Mar; 6(1):19. PubMed ID: 29510745
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma.
Adams AM; Chick RC; Vreeland TJ; Clifton GT; Hale DF; McCarthy PM; O'Shea AE; Bohan PMK; Hickerson AT; Park H; Sloan AJ; Hyngstrom J; Berger AC; Jakub JW; Sussman JJ; Shaheen M; Wagner T; Faries MB; Peoples GE
Melanoma Res; 2021 Aug; 31(4):378-388. PubMed ID: 34193804
[TBL] [Abstract][Full Text] [Related]
4. MRI in the detection of hepatic metastases from high-risk uveal melanoma: a prospective study in 188 patients.
Marshall E; Romaniuk C; Ghaneh P; Wong H; McKay M; Chopra M; Coupland SE; Damato BE
Br J Ophthalmol; 2013 Feb; 97(2):159-63. PubMed ID: 23159448
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell-tumor cell hybrid vaccination for metastatic cancer.
Barbuto JA; Ensina LF; Neves AR; Bergami-Santos P; Leite KR; Marques R; Costa F; Martins SC; Camara-Lopes LH; Buzaid AC
Cancer Immunol Immunother; 2004 Dec; 53(12):1111-8. PubMed ID: 15185011
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma.
Sacco JJ; Carvajal RD; Butler MO; Shoushtari AN; Hassel JC; Ikeguchi A; Hernandez-Aya L; Nathan P; Hamid O; Piulats JM; Rioth M; Johnson DB; Luke JJ; Espinosa E; Leyvraz S; Collins L; Holland C; Sato T
J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38844408
[TBL] [Abstract][Full Text] [Related]
7. Uveal Melanoma: Identifying Immunological and Chemotherapeutic Targets to Treat Metastases.
Jager MJ; Dogrusöz M; Woodman SE
Asia Pac J Ophthalmol (Phila); 2017; 6(2):179-185. PubMed ID: 28399339
[TBL] [Abstract][Full Text] [Related]
8. The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival.
Dewaele S; Delhaye L; De Paepe B; de Bony EJ; De Wilde J; Vanderheyden K; Anckaert J; Yigit N; Nuytens J; Vanden Eynde E; Smet J; Verschoore M; Nemati F; Decaudin D; Rodrigues M; Zhao P; Jochemsen A; Leucci E; Vandesompele J; Van Dorpe J; Marine JC; Van Coster R; Eyckerman S; Mestdagh P
Oncogene; 2022 Jan; 41(1):15-25. PubMed ID: 34508176
[TBL] [Abstract][Full Text] [Related]
9. Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility.
Leonard-Murali S; Bhaskarla C; Yadav GS; Maurya SK; Galiveti CR; Tobin JA; Kann RJ; Ashwat E; Murphy PS; Chakka AB; Soman V; Cantalupo PG; Zhuo X; Vyas G; Kozak DL; Kelly LM; Smith E; Chandran UR; Hsu YS; Kammula US
Nat Commun; 2024 Apr; 15(1):2863. PubMed ID: 38627362
[TBL] [Abstract][Full Text] [Related]
10. From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma.
Synoradzki KJ; Paduszyńska N; Solnik M; Toro MD; Bilmin K; Bylina E; Rutkowski P; Yousef YA; Bucolo C; Zweifel SA; Reibaldi M; Fiedorowicz M; Czarnecka AM
Curr Oncol; 2024 Feb; 31(2):778-800. PubMed ID: 38392052
[TBL] [Abstract][Full Text] [Related]
11. Tumor lysis syndrome induced by tebentafusp.
Ruf T; Leonhardt A; Anz D; Kunz WG; Röhrle N; Foerster P; Tomsitz D; French LE; Seegräber M; Heinzerling L
Immunotherapy; 2023 Nov; 15(16):1363-1368. PubMed ID: 37661909
[TBL] [Abstract][Full Text] [Related]
12. Improving therapy in metastatic uveal melanoma by understanding prior failures.
Olson DJ; Luke JJ
Oncoscience; 2020 May; 7(5-6):40-43. PubMed ID: 32676517
[No Abstract] [Full Text] [Related]
13. Re: Stålhammar G: Delays between uveal melanoma diagnosis and treatment increase the risk of metastatic death (Ophthalmology. 2023 Nov 21:S0161-6420(23)00856-4. doi: 10.1016/j.ophtha.2023.11.021. Online ahead of print).
Hussain RN; Coupland SE; Heimann H; Eleuteri A
Ophthalmology; 2024 Jun; ():. PubMed ID: 38878047
[No Abstract] [Full Text] [Related]
14. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.
Carreno BM; Magrini V; Becker-Hapak M; Kaabinejadian S; Hundal J; Petti AA; Ly A; Lie WR; Hildebrand WH; Mardis ER; Linette GP
Science; 2015 May; 348(6236):803-8. PubMed ID: 25837513
[TBL] [Abstract][Full Text] [Related]
15. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.
Mitchell DA; Batich KA; Gunn MD; Huang MN; Sanchez-Perez L; Nair SK; Congdon KL; Reap EA; Archer GE; Desjardins A; Friedman AH; Friedman HS; Herndon JE; Coan A; McLendon RE; Reardon DA; Vredenburgh JJ; Bigner DD; Sampson JH
Nature; 2015 Mar; 519(7543):366-9. PubMed ID: 25762141
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting.
Lipson EJ; Sharfman WH; Chen S; McMiller TL; Pritchard TS; Salas JT; Sartorius-Mergenthaler S; Freed I; Ravi S; Wang H; Luber B; Sproul JD; Taube JM; Pardoll DM; Topalian SL
J Transl Med; 2015 Jul; 13():214. PubMed ID: 26143264
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study.
de Rosa F; Ridolfi L; Ridolfi R; Gentili G; Valmorri L; Nanni O; Petrini M; Fiammenghi L; Granato AM; Ancarani V; Pancisi E; Soldati V; Cassan S; Riccobon A; Parisi E; Romeo A; Turci L; Guidoboni M
J Transl Med; 2014 Jul; 12():209. PubMed ID: 25053129
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
Algazi AP; Tsai KK; Shoushtari AN; Munhoz RR; Eroglu Z; Piulats JM; Ott PA; Johnson DB; Hwang J; Daud AI; Sosman JA; Carvajal RD; Chmielowski B; Postow MA; Weber JS; Sullivan RJ
Cancer; 2016 Nov; 122(21):3344-3353. PubMed ID: 27533448
[TBL] [Abstract][Full Text] [Related]
19. A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma.
Lee JH; Lee Y; Lee M; Heo MK; Song JS; Kim KH; Lee H; Yi NJ; Lee KW; Suh KS; Bae YS; Kim YJ
Br J Cancer; 2015 Dec; 113(12):1666-76. PubMed ID: 26657650
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma.
Krishnadas DK; Shusterman S; Bai F; Diller L; Sullivan JE; Cheerva AC; George RE; Lucas KG
Cancer Immunol Immunother; 2015 Oct; 64(10):1251-60. PubMed ID: 26105625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
